Breakthrough sensor to help people with bipolar disorder monitor lithium levels

August 28, 2018, University of Surrey
Breakthrough sensor to help people with bipolar disorder monitor lithium levels
Credit: University of Surrey

Patients living with bipolar disorder and depression will soon be able to use a unique wearable sensor to safely monitor their lithium drug levels.

In a study published by the journal ACS Sensors, researchers from the University of Surrey detail how they produced what is believed to be the world's first fibre-based which are ready-to-use to test levels after production. Unlike current sensors on the market that are not wearable, there is no need for pre-conditioning of the sensor in solution for hours beforehand or on a daily-basis.

Lithium is an antipsychotic drug used to treat mood conditions such as and . The drug must be carefully monitored when given to patients, as the wrong dose could prove to be highly toxic. Lithium levels initially need to be checked five to seven days after the first dose, followed by weekly checks until levels stabilise between two doses—after which levels are typically monitored every three months.

The new miniature sensors were shown to quickly and accurately detect lithium concentration levels—from clinically effective, to toxic concentration limits. The sensor is able to detect lithium concentration in the blood even if there is a high of sodium.

Dr. Carol Crean, Senior Lecturer in Physical and Material Chemistry at the University of Surrey, said: "We believe that our new sensors will help many people across the world living with mood disorders, such as bipolar and depression. Our sensors will give those who are receiving treatment the opportunity to monitor their lithium levels with a stable and easy to use wearable sensor. They will give people a real alternative to the currently available invasive blood samples, making monitoring their lithium levels as easy as putting on a t-shirt."

According to the Mental Health Foundation, there were four million cases in the UK of , including bipolar and depression, and major depression is thought to be the leading cause of disability worldwide.

Explore further: Lithium treatment for bipolar disorder linked to lowest risk of rehospitalisation

More information: Mona N. Sweilam et al, Fabrication and Optimization of Fiber-Based Lithium Sensor: A Step toward Wearable Sensors for Lithium Drug Monitoring in Interstitial Fluid, ACS Sensors (2018). DOI: 10.1021/acssensors.8b00528

Related Stories

Gene breakthrough on lithium treatment for bipolar disorder

November 8, 2017

Genes linked to schizophrenia in psychiatric patients suffering from bipolar disorder are the reason why such patients don't respond to the "gold standard" treatment for bipolar - the drug lithium - according to international ...

The hunt for a successor to lithium for bipolar disorder

March 27, 2013

Toxicity problems and adverse side effects when taking lithium, the mainstay medication for treating bipolar disorder, are fostering a scientific hunt for insights into exactly how lithium works in the body—with an eye ...

Recommended for you

New targets in the battle against antibiotic resistance

November 16, 2018

Bacteria are increasingly resistant to available antibiotics. A team of chemists from the Technical University of Munich (TUM) have now identified important enzymes in the metabolism of staphylococci. Blocking these enzymes ...

AI heralds new frontiers for predicting enzyme activity

November 16, 2018

Researchers from the Departments of Chemistry and Engineering Science at the University of Oxford have found a general way of predicting enzyme activity. Enzymes are the protein catalysts that perform most of the key functions ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.